**Table 1** Characteristics, treatments, and outcomes of the 4 patients with relapsed ALCL

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Patients | 1 | 2 | 3 | 4 |
| Initial diagnosis | | | | |
| Age (year)/sex (M, F) | 8/M | 13/M | 7/M | 4/M |
| St. Jude Stage | III | I | IV | III |
| B symptoms | Yes | No | Yes | Yes |
| First-line treatment | CCCG-BNHL-2010 | CCCG-BNHL-2010 | CCCG-BNHL-2010 | CCCG-BNHL-2010 |
| Cumulative vincristine dose (mg/m2) | 18 | 10.5 | 16.5 | 18 |
| First relapse | | | | |
| Time to relapse (months post initial diagnosis) | 26 | 12 | 7 | 57 |
| Site of relapse | Lymph nodes and mediastinal involvement | Lymph nodes, mediastinal involvement and extranodal disease (gut and bone) | Lymph nodes | Lymph nodes |
| Immunophenotype | ALK(+), EMA(–), CD30(+), CD3(-), CD43(+), CD2(+), CD20(-), CD34(-), TdT(-) | ALK(+), EMA(+), CD30(+), CD3(+), CD43(+), CD2(+), CD20(-), CD34(-) | ALK(+), EMA(+), CD30(+), CD3(+), CD43(+), CD20(-), CD34(-), TdT(-) | ALK(+), EMA(+), CD30(+), CD43(+), CD2(+), CD20(-), CD34(-) |
| Response to 2 cycles of weekly vinorelbine | CR | CR | CR | CR |
| Subsequent therapy after 2 cycles of weekly vinorelbine | Single-drug vinorelbine therapy + Auto-HSCT | Single-drug vinorelbine therapy + Auto-HSCT | Single-drug vinorelbine therapy + Allo-HSCT | Multidrug regimen + crizotinib |
| Total cycles of weekly vinorelbine applied before multidrug regimen or transplantation | 7 | 5 | 11 | 2 |
| Outcome | | | | |
| First relapse to subsequent relapse (months) | 18 | 24 | NA | NA |
| Treatment of subsequent relapse | Multidrug regimen + crizotinib | Multidrug regimen + crizotinib | NA | NA |
| Disease status at last evaluation (March 1st, 2020) | CR | CR | CR | CR |
| Duration of follow-up after first relapse (months) | 40 | 39 | 33 | 18 |

*M*, male; *F*, female; *B symptoms*, temperature >38 °C, night sweats, or unexplained weight loss of more than 10% in prior 6 months; *CR*, complete remission; *Auto-HSCT*, autologous peripheral blood stem cell transplantation; *Allo-HSCT*, allogeneic hematopoietic stem cell transplantation; *NA*, not applicable.